Published in final edited form as:

Clin Lymphoma Myeloma Leuk. 2013 June ; 13(3): 315–318.e2. doi:10.1016/j.clml.2013.01.001.

Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia

Alfonso Quintás-Cardama, Hagop Kantarjian, Sherry Pierce, Jorge Cortes, and Srdan Verstovsek

Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

Abstract

A fraction of patients with myelofibrosis (MF) will progress to acute myeloid leukemia (AML) but no current tools are available to identify such patients. By multivariate analysis of 649 patients with MF, we have identified several independent prognostic factors for death. Among those factors, the presence of bone marrow blasts >10% and high risk karyotype were identified as independent risk factors for transformation from MF to AML.

Background—Some patients with myelofibrosis (MF) progress to acute myeloid leukemia (AML). Current prognostic tools were not devised to assess risk of AML transformation.

Methods—Multivariate analysis in 649 patients followed for a median of 19 months (range, 1–180 months).

Results—We identified age > 60 ($P = .004$; hazard ratio [HR], 1.63), platelets $<100 \times 10^9/L$ ($P < .001$; HR, 1.62), bone marrow blast > 10% ($P = .002$; HR, 2.18), high-risk karyotype ($P < .001$; HR, 2.44), transfusion dependency ($P < .001$; HR, 2.64), performance status > 1 ($P = .003$; HR, 1.47), lactate dehydrogenase > 2000 U/L ($P < .001$; HR, 1.62), previous hydroxyurea ($P < .001$; HR, 1.69), and male sex ($P = .005$; HR, 1.41) as independent poor prognostic factors for survival. Using the same baseline variables we identified bone marrow blasts >10% and worst karyotype as independent risk factors for AML transformation. Patients with 1 or both of these risk factors ($n = 80$; 12%) had a median survival of 10 months and a 1-year AML transformation rate of 13% (2% if none of those factors, $P = .001$).

Conclusion—We have identified risk factors that predict high risk of transformation from MF to AML.

Keywords

Acute myeloid leukemia; Death; Progression; Myelofibrosis; Transformation; Prognostic model; Multivariate analysis

© 2013 Elsevier Inc. All rights reserved.

Address for correspondence: Alfonso Quintás-Cardama, MD, M.D. Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030 aquintas@mdanderson.org.

Disclosure The authors have stated that they have no conflicts of interest.

Supplementary Data Supplementary material from this article in the form of a Table, is available online at <http://dx.doi.org/10.1016/j.clml.2013.01.001>.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

The median overall survival (OS) of patients with primary or post-polycythemia vera (PV) or postessential thrombocythemia (ET) myelofibrosis (MF) is 5-7 years.¹ However, particular subsets of patients with MF exhibit highly variable survival times that might exceed 15 years in younger patients with no high-risk features.¹ Several prognostic scoring systems have been devised to risk-stratify patients with MF.¹⁻³ An important cause of death in high-risk MF is transformation to acute myeloid leukemia (AML, ie, myeloproliferative neoplasm [MPN] blast phase), which occurs in 8%-23% of patients with MF in the first 10 years after diagnosis.^{4,5} Patients with MF that transform to AML have a dismal outcome,⁶ with an OS ranging from 3 to 8 months and a 1-year survival rate of 5%-10%.^{4,7}

Though current prognostic models can identify patients with MF with poor prognosis, their ability to predict what patients are at the highest risk of transformation to AML is limited because not all of the risk factors associated with OS in such models independently predict leukemic transformation.³ This is important because prognostic tools capable of identifying patients at the highest risk of death caused by AML transformation might provide an opportunity to intervene early during the course of the disease with specific therapeutic modalities (eg, allogeneic stem cell transplantation [SCT]). On these grounds, we set out to identify independent risk factors that predict for high risk to transformation to AML in a large cohort of patients diagnosed and followed at our institution.

Patients and Methods

The study was approved by the M.D. Anderson Cancer Center Institutional Review Board. We surveyed a database of 649 patients with MF referred to our institution from February 1966 to June 2010, including 177 (27%) with post-PV or post-ET MF (Table 1). The median age was 62 years (range, 20-86 years) and the median bone marrow (BM) blasts was 2% (range, 0%-2%). Splenomegaly was present in 380 patients (59%) and 270 (42%) of them had never received treatment for MF. A complex karyotype was present in 66 patients (10.2%), including 32 (4.9%) with and 34 (5.2%) without deletions of chromosomes 5 and/or 7. AML transformation was established in the presence of ≥20% BM and/or peripheral blood (PB) blasts. Survival was analyzed using the Kaplan-Meier method and differences were compared using the log-rank test.

Results and Discussion

The median follow-up for the whole cohort was 19 months (range, 1-180 months). The yearly rates of AML transformation during the first, second, and third year of follow-up were 3%, 2%, and 3%, respectively. We evaluated an extensive list of baseline patient characteristics by univariate analysis to identify risk factors for OS (Supplementary Table 1), including, among others, previous exposure to alkylating agents, hydroxyurea, immunomodulatory drugs (ie, thalidomide derivatives), MF duration, chromosomal abnormalities, and JAK2^{V617F} mutation (yes vs. no, and as a continuous variable). To determine the relative effect of each variable on survival, a Cox proportional hazard model was constructed entering covariates with a *P* value ≤0.10 in the univariate analysis so as to capture all potential factors independently predicting for survival. The increase in risk was estimated as a hazard ratio (HR). Multivariate analysis identified age ≥60 years (*P* = .004; HR, 1.63; 95% confidence interval [CI], 1.26-2.79), baseline platelet count <100 × 10⁹/L (*P* < .001; HR, 1.62; 95% CI, 1.08-3.21), BM blast >10% (*P* = .002; HR, 2.18; 95% CI, 1.49-3.01), worst karyotype (del17p, -5, -7, and/or complex; *P* < .001; HR, 2.44; 95% CI, 1.51-3.17), transfusion dependency (≥2 red cell transfusions; *P* < .001; HR, 2.64; 95% CI, 0.99-2.01), performance status ≥1 (*P* = .003; HR, 1.47; 95% CI, 1.22-2.11), lactate

dehydrogenase (LDH) > 2000 U/L ($P < .001$; HR, 1.62; 95% CI, 0.89-1.33), previous hydroxyurea ($P < .001$; HR, 1.69; 95% CI, 1.42-2.19), and male sex ($P = .005$; HR, 1.41; 95% CI, 0.88-1.91) as independent poor prognostic factors for OS. Using the corresponding HRs, a risk model for survival was derived based on weighted scores of 0-1, 2-3, 4-5, and

6. The number of patients and median OS for the 4 risk groups were Low, 84 (13%), median OS not reached; Intermediate-1, 191 (29%), median OS 74 months; Intermediate-2, 208 (32%), median OS 29 months; High, 166 (26%), median OS 11 months (Table 2, Figure 1A).

Next, we examined the same baseline variables used in the OS analysis to identify independent risk factors for AML transformation. Multivariate analysis identified white blood cell count $< 3 \times 10^9/L$ ($P = .02$), PB blasts 5% ($P = .01$), BM blasts 5% ($P = .02$), and unfavorable karyotype ($P = .04$). The presence at baseline of BM blasts 10% and worst karyotype were identified as independent poor prognostic factors for both OS and AML transformation. Eighty patients (12% of the cohort) had 1 or both of these 2 risk factors and defined a subgroup of patients with a median OS of only 10 months (Figure 1B). This subgroup was considered to have MF at significantly higher risk (compared with patients without any of these 2 adverse factors) for AML transformation because they had a 1-year transformation-free survival of 82% (vs. 98%; $P < .001$). Ten (13%) of the latter 80 patients carrying any of these 2 risk factors progressed to AML within 12 months of follow-up whereas only 10 (2%) of 568 patients without those factors progressed to AML within the first 12 months of follow-up.

We have identified BM blasts 10% and high-risk karyotype as independent poor prognostic factors for AML transformation. In concert with other studies,^{6,8-11} we failed to identify hydroxyurea therapy as an independent risk factor for AML transformation in MF although it was found to be a factor associated with shorter OS. The critical role of chromosomal abnormalities in AML transformation has been highlighted in studies from the Mayo Clinic.^{4,12,13} Patients with an unfavorable karyotype, and either PB blasts > 9% or leukocytes $> 40 \times 10^9/L$ were initially identified as having > 80% 2-year mortality.¹² Most recently, monosomal karyotype, inv(3)/i(17q) abnormalities, PB blasts 2%, and platelet count $< 41 \times 10^9/L$ were identified as independent predictors of inferior leukemia-free survival.¹³ We had previously reported that PB or BM blasts 10%, platelets $< 50 \times 10^9/L$, and chromosome 17 alterations segregated patients with accelerated phase MF and worse prognosis.¹⁴ In the preset study we confirmed the critical role of genomic losses at chromosome 17 (ie, 17p deletion) in the process of transformation to AML from MF and its association with extremely poor outcomes, likely due to genomic loss at the *TP53* locus.

The molecular mechanisms regulating the progression from MF to AML are incompletely understood. Mutations to several genes encoding epigenetic modifiers such as those involved in DNA hydroxymethylation (eg, *TET2*, *IDH1/2*), in the regulation of histone modifications (eg, *ASXL1*), *IZF1*, or *TP53* have also been linked to AML transformation.^{15,16} Approximately 19% of patients with MPNs acquire mutations in the serine/arginine-rich splicing factor 2 (*SRSF2*) on transformation to MF, which are associated with poor prognosis.¹⁷ While the discovery of these mutations might provide an opportunity for targeted approaches in the future, current approaches for patients with MF who transform to AML are associated with dismal outcomes, with OS ranging from 3 to 8 months and a 1-year survival rate of 5%-10%.^{4,7} In this context, the use of hypomethylating agents such as azacitidine might induce higher response rates and be associated with improved OS compared with those obtained with standard chemotherapy.^{4,7}

Conclusion

Analysis of a large population of patients with either primary or post-PV or post-ET MF identified risk factors that are highly predictive of transformation to AML at any time during the course of MF. Patients with such factors are candidates for more aggressive therapeutic approaches such as allogeneic SCT or experimental therapies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international Working Group for Myelofibrosis Research and Treatment. *Blood*. 2009; 113:2895–901. [PubMed: 18988864]
2. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for myeloproliferative neoplasms research and treatment). *Blood*. 2010; 115:1703–8. [PubMed: 20008785]
3. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol*. 2011; 29:392–7. [PubMed: 21149668]
4. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. *Blood*. 2005; 105:973–7. [PubMed: 15388582]
5. Okamura T, Kinukawa N, Niho Y, et al. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. *Int J Hematol*. 2001; 73:194–8. [PubMed: 11372731]
6. Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. *J Clin Oncol*. 2011; 29:2410–5. [PubMed: 21537037]
7. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). *Blood*. 2010; 116:3735–42. [PubMed: 20664061]
8. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood*. 2005; 105:2664–70. [PubMed: 15585653]
9. Finazzi G, Ruggeri M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. *Br J Haematol*. 2000; 110:577–83. [PubMed: 10997967]
10. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. *Leuk Lymphoma*. 2000; 37:379–85. [PubMed: 10752989]
11. West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. *South Med J*. 1987; 80:323–7. [PubMed: 3824016]
12. Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. *Blood*. 2011; 118:4595–8. [PubMed: 21881047]
13. Tefferi A, Pardanani A, Gangat N, et al. Leukemia risk models in primary myelofibrosis: an international Working Group study. *Leukemia*. 2012; 26:1439–41. [PubMed: 22289985]
14. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. *J Clin Oncol*. 2009; 27:5587–93. [PubMed: 19786661]

15. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. *Nat Rev Cancer*. 2012; 12:599–612. [PubMed: 22898539]
16. Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. *Blood*. 2011; 118:1723–35. [PubMed: 21653328]
17. Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. *Blood*. 2012; 119:4480–5. [PubMed: 22431577]

Clinical Practice Points

- A subset of patients with myelofibrosis (MF) will progress to acute myeloid leukemia (AML) but clinically applicable tools to predict transformation are lacking.
- We conducted a multivariate analysis in 649 patients with MF diagnosed and treated at our institution and identified age > 60, platelets < $100 \times 10^9/L$, bone marrow blast > 10%, high-risk karyotype, transfusion dependency, performance status > 1, lactate dehydrogenase > 2000 U/L, previous exposure to hydroxyurea, and male sex as independent poor prognostic factors for survival.
- Amongst them, bone marrow blasts >10% and high risk karyotype were independent risk factors for AML transformation.
- Patients with one or both of these risk factors had a 1-year rate of transformation to AML of 13% versus only 2% in patients with none of those factors.
- The identification of these risk factors provides a useful tool to detect patients at the highest risk of transformation to AML, which furnishes the opportunity of early therapeutic intervention with allogeneic stem cell transplantation or experimental agents.

Figure 1.

Prognostic Models for Overall Survival (A) and Transformation to Acute Myeloid Leukemia (B) and Survival of Patients With Myelofibrosis Upon Transformation to Acute Myeloid Leukemia (C)

Abbreviations: BM BL = bone marrow blasts; WorstCG = worst cytogenetics (ie, 17p-, -5, -7, and/or complex karyotype).

Table 1

Patient and Disease Characteristics

Parameter	Category	Patients, n (%)	Median (Range)
Age (Years)			62 (20-86)
Hemoglobin (g/dL)			10.4 (1.8-18.7)
Platelets ($\times 10^9/L$)			190 (1-1958)
WBC ($\times 10^9/L$)			9.6 (0.4-361)
% PB Blast			0 (0-17)
% BM Blasts			2 (0-17)
MF Duration (Months)			2.7 (0-353)
LDH (U/L)			1230 (189-1035)
Total Bilirubin (mg/dL)			0.6 (0.1-5.0)
Creatinine (mg/dL)			1.0 (0.4-7.4)
Sex	Female	263 (41)	
Performance Status	0	282 (43)	
	1	314 (48)	
	2	49 (8)	
	3	4 (1)	
Splenomegaly	Yes	380 (59)	
Hepatomegaly	Yes	143 (22)	
Secondary MF	Yes	177 (27)	
Cytogenetics	13q-only	18 (3)	
	20q-only	42 (6)	
	Diploid	367 (57)	
	Insufficient metaphases	17 (3)	
	1 CG Abn	49 (8)	
	2 CG Abn	30 (5)	
	Chromosome 7 Abn	15 (2)	
	Chromosome 17 Abn	7 (1)	
	Complex	34 (5)	
	Complex + 5 Abn	4 (1)	
	Complex + 7 $\pm$ 5 Abn	12 (2)	
	Complex + 17 $\pm$ 5 or 7	16 (2)	
	Not done	38 (6)	
Previous Therapy	Hydrea	238 (37)	
	Immunomodulatory	108 (17)	
	Alkylating	9 (1)	
	Others	24 (4)	
	None	270 (42)	

Abbreviations: Abn = abnormality; BM = bone marrow; CG = cytogenetic; LDH = lactate dehydrogenase; MF = myelofibrosis; PB = peripheral blood; WBC = white blood cell count.

Table 2

Prognostic Scoring System for Overall Survival

Risk Group	Factors, n	Patients, n (%)	Median OS (Months)
Low	0-1	84 (13)	NR
Intermediate-1	2-3	191 (29)	74
Intermediate-2	4-5	208 (32)	29
High	6	166 (26)	11

Abbreviations: NR = not reached; OS = overall survival.

Independent risk factors for survival included in the scoring system: age ≥ 60 years, baseline platelet count $< 100 \times 10^9/L$, bone marrow blast $> 10\%$, high-risk karyotype (del17p, -5, -7, and/or complex), transfusion dependency (≥ 2 red cell transfusions), performance status ≥ 1 , lactate dehydrogenase > 2000 U/L, previous therapy with hydroxyurea, and male sex.